Tags: US | Bristol | Myers | Strategy

Bristol-Myers: 60 Drugs in Testing to Boost Sales

Thursday, 04 Mar 2010 01:24 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Executives at drugmaker Bristol-Myers Squibb Co. are telling analysts at a business briefing they have 60 potential drugs in development, seven in late-stage studies.

The company says it expects future revenue from those medicines and growing sales from existing drugs to help offset an expected plunge in Plavix sales in 2012. That's when U.S. generic competition will start slashing sales of the $6 billion-a-year blood thinner, the world's second-best-selling drug.

The New York-based company's strategy aims to replace that revenue with new drug sales to maintain profits. Bristol-Myers forecasts earnings per share in 2013 will be at least $1.95, a little more than analysts expect.

The business briefing comes two days after news of a CEO change.

© Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

John McCain: Pentagon Press Secretary Is an 'Idiot'

Wednesday, 22 Oct 2014 17:46 PM

A disgusted Sen. John McCain called the Pentagon press secretary an "idiot" for giving a rambling, convoluted assessment . . .

Pastor Defrocked Over Son's Same-Sex Wedding Faces Council

Wednesday, 22 Oct 2014 16:38 PM

A U.S. pastor who was defrocked after officiating at his son's same-sex wedding ceremony, and later reinstated, made an  . . .

Second Ebola Vaccine Enters Human Trials at NIH

Wednesday, 22 Oct 2014 16:30 PM

A second vaccine that could protect against the deadly Ebola virus is entering human trials at the National Institutes o . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved